Comparación de la eficacia y seguridad de flecainida y dronedarona como terapias antiarrítmicas para mantenimiento de ritmo sinusal en fibrilación auricular / Comparison of the efficacy and safety of dronedarone and flecainide as maintenance antiarrhythmic therapy for sinus rhythm in atrial fibrillation

Resumen Introducción y objetivos: Dronedarona y flecainida son antiarrítmicos de primera elección para reducir recurrencias de fibrilación auricular (FA), sin existir estudios que los comparen entre sí. Nuestro objetivo es comparar la eficacia en cuanto a prevención de recurrencias y seguridad de ambos fármacos. Métodos: Estudio retrospectivo en el que se incluyeron 123 pacientes de forma consecutiva en tratamiento con flecainida o dronedarona desde octubre de 2010 hasta febrero de 2013 por FA paroxística (76.4%) y FA persistente (23.6%). Se realizó cardioversión eléctrica en un 7.3% de los pacientes y farmacológica en un 16.3%. La mediana (rango intercuartílico) de seguimiento fue de 301 días (92-474), con una media de 2.8 revisiones por paciente. Se realizó análisis de tiempo hasta el primer evento mediante Kaplan-Meier y regresión de Cox ajustada por un índice de propensión. Resultados: De entre los 123 sujetos incluidos con FA, 71 fueron tratados con flecainida y 52 con dronedarona. Durante el seguimiento se registraron 36 recurrencias y 20 efectos adversos. Se documentaron un 36.6% de recurrencias en los pacientes tratados con flecainida en comparación con un 21% en los tratados con dronedarona (p = 0.073). En el análisis multivariante, dronedarona se mostró al menos tan eficaz como flecainida para prevenir recurrencias de FA (HR: 0.53, IC 95%: 0.20-1.44, p = 0.221) y demostró un perfil de seguridad comparable al de flecainida (HR: 0.68, IC 95%: 0.18-2.53, p = 0.566). Conclusiones: Según nuestra experiencia, dronedarona resulta al menos tan eficaz como flecainida para el mantenimiento de ritmo sinusal, con un buen perfil de tolerabilidad, a pesar de pautarse en pacientes con un perfil clínico más desfavorable.

Abstract Introduction and objectives: Dronedarone and flecainide are the first pharmacological choice to reduce recurrence of atrial fibrillation (AF); however, there are no studies comparing them. A study was performed to compare the efficacy in terms of recurrence of AF and safety of both drugs. Methods: A retrospective cohort study was conducted that included 123 consecutive patients treated with flecainide or dronedarone due to paroxysmal AF (76.4%) or persistent AF (23.6%), from October 2010 to February 2013. Electrical cardioversion was performed in 7.3% of patients and pharmacological cardioversion in 16.3%. The median (interquartile range) follow-up was 301 days (92-474) with a mean of 2.8 reviews per patient. Time to first event analysis was performed using Kaplan-Meier and Cox regression, adjusted for propensity score. Results: Of the 123 consecutive patients with AF included, 71 were on dronedarone and 52 on flecainide. During the follow-up, there were 36 AF recurrences and 20 safety events. There were recurrences in 36.6% of patients treated with flecainide, compared with 21% of those receiving dronedarone (P = .073). Dronedarone showed to be at least as effective as flecainide in preven- ting recurrence of atrial fibrillation (HR: 0.53, 95% CI: 0.20-1.44, P = .221), and demonstrated an acceptable safety profile when compared with flecainide (HR: 0.68, 95% CI: 0.18-2.53, P = .566). Conclusions: In our experience, dronedarone has been at least as effective and safe as flecainide, despite it was most frequently prescribed in patients with worse baseline risk profile.

Intractable Atrial Flutter Successfully Treated with Flecainide and Propranolol in a Premature Infant / 이화의대지

Although Atrial flutter (AFL) in newborn infant with normal cardiac anatomy has benign clinical course, an intractable AFL is associated with an increased risk of development of heart failure and sudden death, and is still difficult to manage. It requires multiple external electrical cardioversions, and it shows a poor response to antiarrhythmic drug therapy. We report a case of a premature infant with an intractable AFL, which we successfully treated with oral flecainide and propranolol in spite of recurred AFL. A 1-month-old, 34-week gestation, premature baby presented with an irregular heart beat and irritability. An AFL with 2:1 atrioventricular conduction was documented. Because of the intractable AFL, repeated electrical cardioversion and amiodarone were continued for 14 days. However, amiodarone was discontinued in favour of flecainide and propranolol because of the recurrent AFL and newly developed transient hypothyroidism. During 1-year follow-up period, in which oral flecainide and propranolol were continued, no AFL was observed.

Flecainide-Induced Torsade de Pointes Successfully Treated with Intensive Pharmacological Therapy

Flecainide acetate is a potent class IC anti-arrhythmic drug with a major sodium channel blocking effect. Flecainide toxicity can cause myocardial impairment and precipitate circulatory collapse. It may also result in life-threatening arrhythmia, although cases of flecainide-induced torsades de pointes are rare. Furthermore, the electrical and hemodynamic deteriorations observed during flecainide toxicity may not respond to conventional treatments. In the present study, we report the case of a 20-year-old Korean man with flecainide poisoning, who presented with hypotension. The patient was successfully treated with sodium bicarbonate, amiodarone, MgSO₄, and lidocaine, with no recourse to extracorporeal therapy. Although there is no standard therapy for flecainide toxicity, this report demonstrates that intensive pharmacological treatment is beneficial in cases of flecainide overdose.

Flecainide Improve Sepsis Induced Acute Lung Injury by Controlling Inflammatory Response / 대한구급학회지

BACKGROUND: Flecainide is an antiarrhythmic agent that is used primarily in the treatment of cardiac arrhythmias. Some evidences also suggest that flecainide can participate in alveolar fluid clearance and inflammatory responses. This experiment was aimed to evaluate the effects of flecainide on sepsis induced acute lung injury in a rat model. METHODS: Rats were treated with subcutaneous infusion of saline or flecainide (0.1 or 0.2 mg/kg/hr) by a mini-osmotic pump. Subcutaneous infusion was started 3 hours before and continued until 8 hours after intraperitoneal injection of saline or endotoxin. Animals were sacrificed for analyses of severity of acute lung injury with wet to dry (W/D) ratio and lung injury score (LIS) in lung and inflammatory responses with level of leukocyte, polymorphonuclear neutrophils (PMNs) and inteleukin-8 (IL-8) in bronchoalveolar lavages fluid (BALF). RESULTS: Flecainide markedly improved dose dependently sepsis induced acute lung injury as analysed by W/D ratio (from 2.24 ± 0.11 to 1.76 ± 0.09, p < 0.05) and LIS (from 3 to 1, p < 0.05), and inflammatory response as determined by leukocyte (from 443 ± 127 to 229 ± 95, p < 0.05), PMNs (from 41.43 ± 17.63 to 2.43 ± 2.61, p < 0.05) and IL-8 (from 95.00 ± 15.28 to 40.00 ± 10.21, p < 0.05) in BALF. CONCLUSIONS: Flecanide improve sepsis induced acute lung injury in rats by controlling inflammatory responses.

Flecainide Improve Sepsis Induced Acute Lung Injury by Controlling Inflammatory Response / 대한중환자의학회지

BACKGROUND: Flecainide is an antiarrhythmic agent that is used primarily in the treatment of cardiac arrhythmias. Some evidences also suggest that flecainide can participate in alveolar fluid clearance and inflammatory responses. This experiment was aimed to evaluate the effects of flecainide on sepsis induced acute lung injury in a rat model. METHODS: Rats were treated with subcutaneous infusion of saline or flecainide (0.1 or 0.2 mg/kg/hr) by a mini-osmotic pump. Subcutaneous infusion was started 3 hours before and continued until 8 hours after intraperitoneal injection of saline or endotoxin. Animals were sacrificed for analyses of severity of acute lung injury with wet to dry (W/D) ratio and lung injury score (LIS) in lung and inflammatory responses with level of leukocyte, polymorphonuclear neutrophils (PMNs) and inteleukin-8 (IL-8) in bronchoalveolar lavages fluid (BALF). RESULTS: Flecainide markedly improved dose dependently sepsis induced acute lung injury as analysed by W/D ratio (from 2.24 ± 0.11 to 1.76 ± 0.09, p < 0.05) and LIS (from 3 to 1, p < 0.05), and inflammatory response as determined by leukocyte (from 443 ± 127 to 229 ± 95, p < 0.05), PMNs (from 41.43 ± 17.63 to 2.43 ± 2.61, p < 0.05) and IL-8 (from 95.00 ± 15.28 to 40.00 ± 10.21, p < 0.05) in BALF. CONCLUSIONS: Flecanide improve sepsis induced acute lung injury in rats by controlling inflammatory responses.

Drug Interaction of Amiodarone, Flecainide, Metoprolol and Diltiazem leading to Heart Block.

Amiodarone, flecainide, metoprolol and diltiazem individually are known to cause heart blocks due to their cardiac depressant property but the current case report is worth reporting because it resulted because of drug interaction of multiple drugs due to possible medication error.

Manejo terapeútico de algunas arritmias fetales / Therapeutic management of some fetal arrhythmias

Introducción: la electrocardiografía fetal constituye la prueba de oro para el diagnóstico de las arritmias en la vida posnatal, algo difícil de lograr en la vida prenatal incluso con la ecografía prenatal de alta resolución. Las taquiarritmias supraventriculares son las que se manifiestan con frecuencias cardíacas superiores a 180 latidos por min y pueden asociarse a mortalidad fetal en un tercio de los casos, sobre todo cuando se asocia a hidropesía fetal o cuando se establece por más de 15 días. El tratamiento permite la reversión de la arritmia o el control ventricular en el menor tiempo posible. Objetivos: comprobar la respuesta intraútero de la taquiarritmia al tratamiento farmacológico. Métodos: se realizó un estudio descriptivo prospectivo observacional de un universo de 24 fetos con el diagnóstico de taquiarritmia fetal que se diagnosticaron y atendieron en el Departamento Provincial de Genética de La Habana y en el Hospital Ginecobstétrico "Ramón González Coro" entre los años 2003 y 2012. Resultados: las taquiarritmias se observaron en 24 fetos (40,6 %). Las madres menores 30 años fueron las más representadas en el grupo de mujeres del estudio, unido al índice de masa corporal sobrepeso y específicamente las pacientes nulíparas. Casi la mitad de la muestra no requirió tratamiento farmacológico (45,8 %) todas con el diagnóstico ecocardiográfico de extrasístoles y sola una con compromiso orgánico del corazón. Conclusiones: la flecainida se utilizó, en la cuarta parte de la muestra y mostró una resolutividad de 83,3 % en los fetos intraútero. La sobrevida de los fetos tratados farmacológicamente por vía oral fue 100 %.

Introduction: fetal electrocardiography is the gold standard for diagnosis of arrhythmias in postnatal life. This is difficult to achieve in prenatal life even with high-resolution prenatal ultrasound. Supraventricular tachyarrhythmias are manifested with heart rates above 180 beats per min and may be associated with fetal death in one third of cases, especially when associated with fetal hydrops or when it is set for over 15 days. Treatment allows the reversal of ventricular arrhythmia or control in the shortest possible time. Objective: to test tachyarrhythmia in uterus response to drug treatment. Methods: an observational prospective descriptive study was conducted in a universe of 24 fetuses with the diagnosis of fetal tachyarrhythmia that were diagnosed and treated at the Provincial Department of Genetics, Havana and at the Ramón González Coro Maternal Hospital from 2003 to 2012. Results: tachyarrhythmias were observed in 24 fetuses (40.6 %). Mothers younger than 30 were the most represented in this study group, together with BMI overweight and nulliparous patients specifically. Almost half of the sample did not require drug (45.8 %) treatment, all with extrasystoles echocardiographic diagnosis and only one with organic heart involvement. Conclusions: flecainide was used in a quarter of the sample and showed 83.3 % resoluteness of fetuses in uterus. Survival of fetuses pharmacologically orally treated was 100 %.

A Case of Life-Threatening Supraventricular Tachycardia Related to Flecainide Toxicity / 대한내과학회지

Flecainide acetate is a potent class Ic anti-arrhythmic drug with a major sodium channel-blocking effect. Flecainide toxicity can cause myocardial impairment and precipitate circulatory collapse, particularly in patients with renal failure. Electrical and hemodynamic deterioration during flecainide toxicity may not respond to conventional treatments. We report the successful management of flecainide toxicity using extracorporeal membrane oxygenation (ECMO), hemoperfusion, and bicarbonate administration maintaining alkalinity.

Perimortem cesarean section in a pregnant woman with flecainide-induced ventricular tachycardia: A case report

Flecainide is a drug used to manage supraventricular and ventricular arrhythmias. It is also effective in the treatment of fetal tachyarrhythmia through administration to the mother. However, flecainide toxicity may cause serious complications, including cardiac conduction disturbance, ventricular arrhythmia, resulting in syncope and sudden death. We describe here a 27-year-old woman at 31 weeks of gestation who experienced ventricular tachycardia, leading a perimortem cesarean section. On her past medication history, she has taken overdose of oral flecainide for the treatment of fetal atrial flutter. Just after neonatal delivery, her ventricular tachycardia was successfully reverted to a sinus rhythm through administration of intravenous lidocaine and hemodynamics were stabilized. According to her clinical signs and symptoms, we presume the ventricular tachycardia was likely induced by flecainide toxicity, although serum flecainide concentration could not be measured in our institution.

A Case of Acute Ventricular Capture Threshold Rise Associated with Flecainide Acetate

Antiarrhythmic agents may increase capture threshold, but this is rarely of clinical significance. Flecainide acetate, a class IC agent, is reported to have a significant effect on the myocardial capture threshold. In this presentation, we report the case of a 72-year-old male, with a previously implanted VVI pacemaker due to sick sinus syndrome, who was treated with flecainide acetate for paroxysmal atrial arrhythmia control. During the fifteenth day of treatment, an abrupt rise in the ventricular capture threshold with ventricular pacing failure was noted. The capture threshold decreased two days after discontinuation of flecainide acetate.

Wide QRS tachycardia during treatment with class ic antiarrhythmic agents in a patient with atrial fibrillation: report of 2 cases / 대한내과학회지

Wide QRS tachycardia may represent a rare proarrhythmic effect of some antiarrhythmic agents. Class Ic antiarrhythmic agents produce rate- dependent ventricular conduction slowing due to use-dependent sodium channel blockade, causing QRS prolongation in cases with an increased heart rate. The authors describe two cases of atrial flutter with 1:1 atrioventricular conduction exhibiting a wide QRS tachycardia while on therapy using flecainide and propafenone, and the difficulty in interpreting the ECG.

Wide QRS tachycardia during treatment with class ic antiarrhythmic agents in a patient with atrial fibrillation: report of 2 cases / 대한내과학회지

Wide QRS tachycardia may represent a rare proarrhythmic effect of some antiarrhythmic agents. Class Ic antiarrhythmic agents produce rate- dependent ventricular conduction slowing due to use-dependent sodium channel blockade, causing QRS prolongation in cases with an increased heart rate. The authors describe two cases of atrial flutter with 1:1 atrioventricular conduction exhibiting a wide QRS tachycardia while on therapy using flecainide and propafenone, and the difficulty in interpreting the ECG.

Comparision of thr Efficacy of Propafenone and Flecainide in Patients with Atrial Fibrillation

BACKGROUND: Atrial fibrillation is one of the most common cardiac arrhythmias which has been recieved relatively little attention until recently.Despite the variety of treatment modalities including drugs,surgery,catheter ablation and devices,the overall treatment of atrial fibrillation is not always satisfactory.Phalmacotherapy is still the most commonly used treatment through the unfavorable side effects of antiarrhythmic drugs are problematic.The purpose of this study is to compare the efficacy of class Ic antiarrhythmic drugs,propafenone versus flecainide. METHODS: We treated one hundred eighteen patients with atrial fibrillation by class Ic antiarrhythmic drugs,propafenone or flecainide with/without DC cardioversion to convert to and maintain the sinus rythm. We compared the clinical findings,drug efficacy,side sffects of drugs between two groups. RESULTS: 30 patients were treated by propafenne and 88 patients by flecainide.21 and 60 patients in each group were lone atrial fibrillation,14 and 49 patients were paroxysmal atrial fibrillation.Mean duration of drug administration were 360.9,339.4 days,respectively.The convesion rate to sinus rhythm by drugs was 25.0% in propafenone group and 30.7% in flecainide group(p=NS).The 300 days-manitenance rates of sinus rhythm after conversion by drugs or DC cardioversion were 63,3%,70.4%(p=NS)respectively. The side effects of drugs were dizziness,nausia and vomitting in both group and 1st degree AV block,transient sinus node dysfunction and decreased visual acuity in flecainde group.The drugs were discontinued in 11(37.7%) and 26(29.5%) patients in each group due to recurrence of atrial fibrillation or side effects of drugs. CONCLUSION: This study suggests that propafenone and flecainide are comparably effective in maintaining sinus rhythm in atrial fibrillation patients.Futher prospective and large study is required to confirm this findings.